A Pan-European Non-interventional, Retrospective Observational Cohort Study of Patients With BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer Treated With Olaparib Tablets in the First-line Maintenance Setting
Latest Information Update: 27 Jan 2023
At a glance
- Drugs Olaparib (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms OVAL-1
- Sponsors AstraZeneca
- 15 Nov 2022 Status changed from recruiting to active, no longer recruiting.
- 28 Jan 2021 Status changed from not yet recruiting to recruiting.
- 02 Sep 2020 New trial record